Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Look about right?
Date Brokerage Action Rating Price Target
7/3/19 Oppenheimer Init Cov Outperform $15.00 Matthew Biegler
7/23/19 Roth Capital Init Cov Buy $10.00 Tony Butler
3/29/19 WBB upgrade Strong buy $12.50 Steve Brozak
?? Janney upgrade $15.00 Yun Zhong
12/3/18 Piper Jaffray Upgrade overweight $10 Edward Tenthoff
11/21/18 Nomura Init Cov Buy $16.00 Christopher Marai
"Looking ahead, Tony Butler also said there’s a 70% chance the company’s therapy will win government approval followed by commercialization during 2024. After the launch we assume relatively rapid uptake with competitive peak penetrations the US (30%), Europe (20%), and China (10%),” he added. 7/23
Mathew Biegler sees the Phase 2 trial in AML supporting a streamlined path to market, while multiple readouts from ongoing academic-sponsored trials could de-risk MultiTAA in additional indications.
Steve Brozak comments, following the reported encouraging news for the treatment of two high-mortality cancers, "AML has been designated as MRKR’s lead indication. The company expects to finalize the protocol for a confirmatory Phase 3 clinical trial by end of 2Q-2019 and to submit an IND in 3Q, with the first patient enrolled by end of year.
are these latest price targets?
Date Brokerage Action Rating Price Target
7/3/19 Oppenheimer Init Cov Outperform $15.00 Matthew Biegler
5/30/19 Roth Capital Init Cov Buy $10.00 Tony Butler, Ph.D
3/29/19 WBB Securities Upgrade Buy ? Strong-Buy $7.29 Steve Brozak, DMH
3/1/19 Janney M. Scott Init Cov Buy ? Buy $6.22 Yun Zhong, Ph.D
12/3/18 Piper Jaffray Upgrade Neut ? Overwt Edward Tenthoff
11/21/18 Nomura Init Cov Buy $16.00 Christopher Marai, Ph.D $16.00 Christopher Marai, Ph.D
Never never doubt that which no one is sure about.
MTAA gains steam with time, per Peter, once epitope spread starts. Look again at page 26.
See page 26, patient 6 on latest deck. I think we could have 2 out of 9 patients with complete response shortly.
https://markertherapeutics.com/wp-content/uploads/2019/08/Marker-Therapeutics-Investor-Presentation-2019-08-08.pdf
Sempre Verde
Marker’s MTAA will be standard of care.
What are odds the that Marker’s Complete Response in stage 4 pancreatic cancer was a fluke?
Are the odds even slimmer when it is verified by definite epitope spread?
Way beyond a reasonable doubt Marker’s treatment works.
Stock is behaving against the clear science.
I believe now is when fortunes are made.
Many many lives will be saved.
Respectfully, shorts disrupt the market. They create artificial supply that artificially suppresses the price.
Shorting is often used to defeat a fragile yet promising company.
Great post.
MD Anderson has a proton beam. Right next door.
Radiation therapy may also poke holes. Maybe MTAA could work with radiation to
increase the abscopal effect. This would be less toxic than chemo as you
may need to only initiate the attack and not a full killing fraction schedule.
Moreover, more targeted proton or carbon ion may be better and less damaging to immune system.
Leen seemed excited that arm a worked.
This might be very important. Arm a was with chemotherapy.
It may be the chemo pokes holes in cancer, allowing
an opportunity for activated targeted tcells to attack.
This might be how the doors will open on other solid cancers.
I feel VERY confident about MTAA.
Stay Strong my friends. Relief is nearby.
Congratulations Leen, Vera, Peter and all the rest at Baylor/ Marker.
Thank you
Nonsense! Rubbish!
Pancreatic cancer is a monster.
But...
1/9 radiographic complete response. ~50 stable over 6 months.
On first try. Non-optimized. No side effects.
This is fantastic news.
A milestone.
Who would not want to take this... ASAP
Check @drsmags on Twitter.
Hi Anti,
Please advise how you know short interest borrow rate.
If it is Fidelity –– is this representative of other borrow fees? Thanks
THE WHY
Why no epitope spreading with CAR-T?
Because ... CAR-T wipes out immune system before transplanting engineered immune system.
MTAA causes epitope spreading because immune system remains viable.
It is the viable immune system that finds those rare epitopes and goes to work.
MTAA works with the immune system, CAR-T over-rides the immune system.
Have respect for Mother Nature, she’s been doing this for a while. Work WITH her..
IMHO
GLTA
Hi Attila, Thanks for updates.
Would anyone know how much time is needed to prepare a treatment (in G-rex device) for infusion once blood is drawn? 4 weeks?
Does Peter, or Baylor, typically only announce new results at conferences?